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Based on the promise of liposomes as convenient vehicles for the transport of boronated agents for the boron 
neutron capture therapy (BCNT) of cancer, this paper reports a method for the formulation and characterisation 
of stable o-carborane-loaded liposomes (ca. 80 – 100 nm) of dipalmitoyl-phosphatidylcholine (DPPC) or 1,2-
distearol-sn-glycerol-3-phosphocholine (DSPC). Preliminary pharmaceutical characterisation experiments have 
demonstrated the integrity of both DPPC and DSPC liposomal membranes in serum and in PBS and also indicate 
that these o-carborane-loaded liposomes are candidate carrier vehicles for further evaluation with a view to 
exploitation in BNCT. 
 








Boron neutron capture therapy (BNCT) uses a low-energy neutron beam directed at a tumour to bring about its 
selective destruction through interaction with administered boronated agents [1-3]. A localised nuclear fission 
reaction takes place within 10B-containing tumour cells, which are consequentially destroyed by the produced α-
particles (1.47 MeV) and recoiling 7Li nuclei (0.84 MeV) [4,5]; the therapeutically useful amount for BNCT is 
ca. 20-30 µg 10B/g tumour [6]. Although BNCT is considered suitable for many types of cancers (head and neck 
[7], hepatic [8], lung [9] and gastrointestinal [8]), most BNCT-related activities have been focused on brain 
tumours (gliomas), largely due to the risks associated with debulking [10]. 
Carboranes are caged polyhedral molecules that are regarded as promising boron-moieties agents for 
BNCT, owing to their high molar boron content, neutral charge and good stability [11-13]. These molecules are 
highly lipophilic [14] but readily amenable to functionalisation with hydrophilic moieties [15,16]. This 
functionalisation is rendered tuneable by the type (ortho- ‘o-’, meta- ‘m-’ or para ‘p-’) of progenitor carborane 
[17], all of which are biocompatible [18]. A growing body of evidence suggests that carboranes may be capable 
of being transported, although not intrinsically, across the blood-brain-barrier (BBB) [19] via small unilamellar 
vesicular (SUV, dia. < 100 nm) liposomes [20,21]. Typically, these carriers are comprised of a lipid bilayer [22,23] 
that is stabilised through co-formulation with cholesterol molecules [24]. 
A diverse array of anti-cancer strategies involving liposomes continue to be developed [25,26]. Liu et al. 
reported a reduction in cell migration in triple negative breast cancer through use of liposomes functionalised with 
a C-X-C chemokine receptor type 4 (CSCR4, CD184) binding peptide (DV1) [27]. Liposomes immobilised with 
antibodies to target chronic inflamed endothelium, which plays a role in cancer and atherosclerosis [28].  Soft 
nanolipogels (NLGs, lipid bilayers encapsulating an alginate core) are reported to have higher cellular (neoplastic 
and non-neoplastic) uptake with respect to more elastic NLGs, although these particles have diameters of ca. 150 
nm [29]. Huwyler et al. encapsulated daunomycin into PEGylated liposomes (85 nm), each coupled to 30 OX26 
antibodies [30,31]. These are reported to accumulate successfully in brain tissue by overcoming the BBB 
limitation. Similar transport across the BBB is reported to have been achieved with liposomes (<100 nm) 
containing nerve growth factors (NGFs; 34% encapsulation) [32]. For selective delivery to neoplastic tissues 
[33,34], boronated agents may be encapsulated within the vacant polar inner space of liposomes or, in the case of 
polyhedral boranes, such as with o-carborane, incorporated within the lipid double-layers [33,35]. 
Rationalised by the promise of thin-film-method preparation [36], o-carborane-loaded, small (<100 nm 
diameter), stable SUV liposomes to cross the BBB and to avoid recognition by macrophages [37], the current 
study focusses on structures of dipalmitoyl-phosphatidylcholine (DPPC) or 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) in co-formulation with cholesterol. Liposomal stability is assessed by means of ζ-
potential measurements and by evaluation of the retention of the hydrophilic marker calcein in phosphate-buffered 
saline (PBS, pH 7.4) and in human serum. o-Carborane incorporation is assessed spectrophotometrically by the 
displacement of Nile red method, and 10B content is quantified by the inductively coupled plasma - mass 







DPPC and DSPC were obtained from Lipoid (≥99%; Ludwigshafen am Rhein, Germany). Potassium chloride 
(ACS Reagent), potassium phosphate dibasic (K2HPO4; ACS Reagent), cholesterol (≥99%), calcein (AR Grade), 
Nile red (Technical grade), Triton X-100 (Laboratory grade), conc. sulphuric acid (ACS reagent) and hydrogen 
peroxide (ACS reagent) and sephadex G-50 were provided by Sigma-Aldrich (Dorset, UK). Syringe filters (0.2 
μm, PES 25 mm; GD/X sterile; Whatman), ethanol (Absolute), chloroform (ACS Reagent), sodium chloride (SLR 
grade), sodium phosphate monobasic (99%; NaH2PO4), sodium hydroxide (ACS Reagent), hydrochloric acid (AR 
grade) and o-carborane (98%; Alfa Aesar) were obtained from ThermoFisher Scientific (Loughborough, UK). 
NaOH (20%) and HCl (2M) were prepared in the laboratory. 
DPPC and DSPC liposomes incorporating specified amounts of o-carborane were prepared using the 
thin-film method. 
 
2.2. Preparation of phosphate buffered saline (PBS, pH 7.4) 
 
PBS (1 L) was made containing NaCl (8.00 g), KCl (0.19 g), KH2PO4 (0.2 g), Na2HPO4 (1.7 g) and adjusted to 
pH 7.4. 
 





Calcein stock solution (50 mM) was prepared by dissolving calcein in distilled water with dropwise addition of 
NaOH until the powder was completely dissolved [19]. The pH of the calcein solution was adjusted to pH 7.4. 
The solution was then made up to 10 mL, filtered, placed in an amber bottle wrapped in aluminium foil and stored 
in the refrigerator (4 °C). 
 
2.4. Preparation of serum stock solution from rat blood 
 
Plasma stock solution was made using whole blood: rat blood (20 mL) was placed in a beaker and placed in an 
incubator (37 °C, 30 min). A long Pasteur pipette was used to separate the thus clotted blood from the wall of the 
beaker. The clotted blood was transferred into separate Eppendorf tubes, cooled (4 °C, 10 min) and centrifuged 
(3000 rpm, 10 min) to effect the separation of plasma. The serum, which appeared as a clear yellowish liquid layer 
on top of the clotted blood, was transferred into new Eppendorf tubes (plastic pipette) and centrifuged (3000 rpm) 
for a further 10 min. The separated serum was placed in Eppendorf tubes and stored in the freezer for future use. 
 
2.5. Preparation of Nile red stock solution 
 
For the assessment of liposome o-carborane loading, a Nile red solution in CHCl3 (container wrapped in foil and 
stored at 4 °C) was used to disperse the lipids before forming the thin film. The concentration of Nile red in the 
lipid dispersion was 2.5 μM [19]. 
 
2.6. Preparation of o-carborane stock solutions 
 
In accord with a literature method [21], the selected lipid (DPPC or DSPC; 15 mg) and o-carborane were mixed 
at molar ratios of 1:0.5, 1:1, 1:10, 1:20 and 1:40 to a lipid concentration of 5 mg mL-1. Respective concentrations 
for DPPC and DSPC solutions were 6.8 mM and 6.3 mM and corresponding concentrations for o-carborane were 
3.4, 6.8, 68, 136 and 272 mM and 3.2, 6.3, 63, 126 and 252 mM. Solutions were wrapped in foil and stored at 4 
°C. 
 
2.7. Preparation of DPPC/DSPC liposomes using the thin-film method  
 
DPPC and DSPC liposomes were prepared using the standard thin-film hydration method: DPPC or DSPC (250 
µL) from the stock solution (200 mg per 10 mL, 20 mg mL-1) [38] were placed into three separate flasks. This 
gave a lipid mass of 5 mg (DPPC, 6.8 mM; DSPC, 6.3 mM [19]), required for the low systemic toxicity and 
normal tissue uptake, equivalent to ca. 20 µg / 10B / g tumour. The organic solvent was evaporated under reduced 
pressure (Buchi 461 rotary evaporator, Switzerland) at a temperature 10 °C > lipid phase transition temperature 
(chain melting temperature, Tc = 42 °C DPPC, 54 °C DSPC [39]) and then dried (N2 stream) to yield thin films at 
the air-water interface. These were rehydrated at 60 °C with PBS (3 mL; buffer solution, pH 7.4) and dispersed 
(vortex) to produce empty liposomes [40]. 
Loaded liposomes were prepared using calcein (3 mL; 50 mM) that had been pre-warmed > Tc of DPPC 
(45 °C; 10 min) and added to the prepared thin film. This dispersion was vortexed (5 min) to assist uniform 
dispersion. To decrease the size of liposomal dispersions, the mixture was placed in the bath sonicator (30 min) 
[38,41]. The round-bottomed flask was placed at the air-water interface in the sonicator to ensure efficient particle 
size reduction [42]. 
For the preparation of SUVs, the suspension was subjected to probe sonication (120 s at 2 s intervals; 
Gex 400 Probe Sonicator, Germany) [43]. To remove of Ti fragments, multilamellar vesicles (MLVs) or liposomal 
aggregates, the liposome dispersion was centrifuged (5 min; 3000 rpm). Samples were then annealed [43] for at 
least 1 h at the liposome preparation temperature (above Tm; 50-60 °C, water bath) [43] before loading them onto 
the gel-chromatography columns. For the addition of cholesterol, the lipid : cholesterol ratio was maintained at 
2:1 [19]. 
 
2.8. Preparation of DPPC/DSPC liposomes for fluorescence displacement, particle size measurements and 
ICP-MS 
 
As with the carborane-free liposomes, o-carborane-containing DPPC and DSPC liposomes were prepared using 
the thin-film hydration method. Specified volumes of o-carborane stock solution (e.g. for DPPC liposomes: 0, 
12.5, 25, 250, 500 or 1000 µL; corresponding to 12.5 µL × 3.4 mM = 4.25×10-8 moles of o-carborane), CHCl3 (1 
mL) and Nile red (1000 μL) were pipetted into a round-bottomed flask. The solvent was removed under reduced 





2.9. Calcein stability measurements 
 
To render calcein-loaded vesicles osmotically stable, non-encapsulated calcein was separated from liposomes 
containing calcein on a Sephadex G-50 column (gel-permeation-chromatography, Anachem, Leicester, UK) using 
PBS (pH 7.4) as the eluent; pre-saturation of the column with each lipid, allowed recoveries > 94% [19,44].  
 An aliquot of each solution (40 μL) was placed into separate Eppendorf tubes containing PBS (4 mL; pH 
7.4) [43]. The fluorescence intensity (λem = 495 nm, λex = 520 nm; Varian Inc., USA) was measured immediately 
(t0 = 0 h). Triton X-100 (10%; 400 μL) added and the tube agitated (electrical vortex: 5 s, 2000 rpm) to break 
down the liposomes and release the encapsulated calcein [43,45]. Fluorescence was recorded immediately (0 h) 
and again after 24 h. 
For fluorescence measurements in serum, a similar method was used. The combined volume of samples 
from the columns were divided by 4 and used for each reading, i.e., 200 μL of sample was obtained from each 
column, and 50 μL of serum used for each reading. The ratio of lipid : serum was therefore 1 mL : 40 μL. 
Fluorescence measurements (cuvette) and the procedure for adding Triton X-100 were performed as above, after 
adding the sample (40 μL) to PBS (4 mL, pH 7.4). 
Percent latency (%L) and percent retention (%R) of liposomes (with and without incorporated 





× 100%          (1) 
 
where, Df = dilution factor (1.1), Fbt = fluorescence value before adding Triton X-100, Fat = fluorescence value 




× 100%          (2) 
 
where, %Lt = %L after 24 h and %L0 = %L at the initial time point. 
 
Statistical differences (p < 0.05) between %retention data were evaluated by means of the paired t-test. 
 
2.10. Nile red entrapment measurements  
 
The fluorescence intensities of liposomal solutions containing Nile red were measured under identical conditions 
to those employed for the calcein content measurements (λem = 495 nm, λex = 520 nm; Varian Inc., USA). 
 
2.11. Particle sizing and ζ-potential 
 
Dynamic light scattering (DLS; measurement angle, 173 °) data were obtained for liposomes with or without 
entrapped o-carborane and electrophoresis measurements were performed using a Nano-ZS Zeta at 25 °C (4 mW 
He-Ne laser λ = 633 nm, photodiode detector; Malvern Instruments, UK). PDI and ζ-potential were determined 
at 25 °C. 
 
2.12. ICP-MS Boron analysis 
 
In boron-free glass vials, an aliquot of conc. H2SO4 (500 μL) was added to each of the liposome solutions (600 
µL) in each o-carborane-containing liposome formulation. These solutions, which were observed to became hot 
and progressively darker, were allowed to stand until they cooled to room temperature (< 24 °C). H2O2 (100 µL) 
was added to each tube. When solutions became decolourised, volumes were adjusted to 2 mL by the addition of 
distilled water (800 μL). The 10B content of the mineralised samples and that of the supernatant were determined 
using ICP-MS (700 Series; Agilent Technologies, Santa Clara, CA, USA) operating at 1550 W, with a carrier gas 
flow rate of 0.91 L min-1, make up gas flow of 0.24 L min-1 and a nebuliser pump rate of 0.1 rps. Beryllium and 
10B standard solutions (1000 ppm) were used in the calibration. 
 
2.13. Scanning electron microscopy 
 
Aliquots of solutions containing DSPC liposomes (5 µL), either unloaded or o-carborane (1000 µL) loaded, were 
placed on the surface of freshly-cleaved muscovite mica (Agar Scientific, Stansted, Essex, UK) and left to dry for 
2 min. The surface was rinsed with distilled water, dried in a N2 stream and sputter-coated with Au/Pd in an Argon 
atmosphere (< 0.2 Torr, 18 mA for 5–10 min; Polaron E5000 SEM coating-unit, Quorum Technologies Ltd., East 




(resolution = 4.5 nm, acceleration voltage = 15 kV). Mean particle sizes were obtained through the deployment 
of a scale bar. 
 
2.14. Atomic force microscopy 
 
Liposome samples were prepared as for SEM, but without Au/Pd coating. Atomic force microscopy (AFM) 
studies were carried out using a Multi-Mode / NanoScope IV scanning probe microscope, Bruker, Santa Barbara, 
CA, USA and were performed in air under ambient conditions (T = 23 °C, RH = 21%) using the J-scanner (max. 
xy = 200 µm). Scanning was performed in Tapping mode using Si cantilevers with integrated tips (t = 3.6–5.6 
µm, l = 140–180 µm, w = 48–52 µm, υ0 = 288–338 kHz, k = 12–103 N m-1, R < 7 nm; model: OTESPA, Bruker, 
France), and an RMS amplitude of 0.8 V. The images were subsequently processed and dimensions (particle 
diameters) measured using NanoScope Analysis software (V1.4, Bruker, Santa Barbara, CA, USA). 
 
2.15. Statistical measurements 
 
One-way ANOVA and posthoc (Tukey) analyses were performed using SPSS (Version 24; IBM, Armonk, NY, 
USA) with the exception of the retention results, which were analysed using GraphPad Prism (Version 7.03; 
GraphPad Software, La Jolla, CA, USA). 
 
 
3. Results and discussion 
 
3.1. Particle sizing, PDI and ζ-potential 
 
To minimise particle size, liposome formulations were probe sonicated twice. The effect of re-probing (before 
and after the second probe, 5 min) on particle size, PDI and ζ-potential was investigated for the o-carborane-
loaded DPPC and DSPC liposomes. The data (n = 3) show that re-probing reduces the average particle sizes of 
both DPPC and DSPC liposomes (Table 1) to a range that is deemed suitable for drug delivery across the BBB (< 
100 nm) [46]. Particle sizes were seen to increase with increasing o-carborane loading. The diameters of the 
longer-lipid-chain-length DSPC liposomes were observed to be larger than those of DPPC structures. Indicative 
of monodisperse and homogenous particle size distributions, PDI values for all liposomes were < 0.5. ζ-Potentials 
of between -30 and +30 mV, probably due to the high ionic strength of the PBS medium [19], highlight the 
likelihood of some particle agglomeration. Notably, Awad and co-workers attributed an observed sigmoidal 
decrease in ζ-potential (from -5 to -40 mV) with increasing concentrations of sodium borocaptate (BSH) to the 
interaction between the boron species and the lipid bilayer [45]. 
 
3.2. Stability of liposome properties after one week 
 
Since the ζ-potentials of the liposomes indicated the likelihood of agglomeration, particle sizes were re-measured 
after 1 week of storage in the refrigerator (3-5 °C). Liposomes were probe sonication once before storage, but not 
re-probed after the storage period: particle sizes and PDI values are presented in Table 2. 
Prior to storage, particle size measurements indicated that increasing o-carborane content increases the 
sizes of both DPPC and DSPC liposomes. At the lower range of the specified concentrations, particles sizes were 
within the acceptable (100 nm) range. For DSPC liposomes, particle sizes increased dramatically with increased 
loadings of o-carborane. (PDI values were generally < 0.5, reflecting high monodispersity and homogeneity, but 
some DSPC liposomes of high o-carborane content breached this limit.) On storage, liposome sizes generally 
increased but in a manner that is not linked directly to o-carborane content.  
 
3.3. AFM studies 
 
AFM was used to investigate the long-term stability of o-carborane-containing liposomes. To facilitate the 
observation of changes in the morphology of liposomes and to investigate agglomeration, the liposomes were re-
probed prior to measuring sizes with the AFM. Line profiles were used to obtain particle sizes (diameters) from 
the images of unloaded and loaded DPPC and DSPC liposomes (max. lipid : o-carborane 1:40; Fig. 1; Table 3); 
these were obtained after 1, 19, 35, 49 and 63 days after preparation. Loaded liposomes appeared intact after 63 
days of storage, indicating the suitability of the formulation as a BNCT carrier of o-carborane. Particle diameters 
rather than heights were measured, since the latter are known to be subject to an artefact resulting from possible 
compression of biomaterial under the applied load of the AFM tip in TappingMode [47] (as reflected in the lower-





3.4. SEM studies 
 
To investigate liposome morphology further and to complement particle size data obtained with the zeta sizer and 
with AFM, particle diameters were obtained from SEM images (Fig. 2). Both the unloaded and o-carborane-
loaded (max. lipid : o-carborane 1:40) liposomes were seen to be spherical and featureless. Loaded structures had 
somewhat larger mean diameters than unloaded DSPC liposomes (267 ± 90 and 201 ± 53 nm, respectively; n = 
30 per group; p < 0.05). Sizes were in the range measured using laser diffraction methods (Malvern Nanosizer). 
These findings are consistent with a literature report that o-carborane-loaded 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) liposomes were larger than those of their unloaded congeners [19]. 
 
3.5. Stabilisation of liposomes with cholesterol and serum 
 
To assess the stability of the liposome formulations in physiologically relevant media, the leaching from these 
vehicles was investigated of the water-soluble, hydrophilic fluorescent marker calcein. Towards an understanding 
of the effect of the cholesterol stabilising agent in improving the stability of DPPC and DSPC liposomes, the 
effect of cholesterol inclusions was investigated; cholesterol is known to stabilise liposome formations by 
increasing rigidity and preventing leakage [24]. Studies monitored the release of calcein from liposomes (in the 
absence of o-carborane) following treatment with Triton X-100, which is known to disrupt the lipid bilayer. To 
this end, calcein-containing DPPC and DSPC liposomes were prepared and particle sizes (Fig. 3), PDI values and 
ζ-potentials were determined in PBS medium and in rat serum (37 °C). 
In all cases, DSPC liposomes were observed to be larger than their DPPC congeners (p < 0.05). In the 
absence of cholesterol, both types of liposomes exhibited larger diameter particles in serum than in PSB buffer. 
In accord with expectation, the incorporation of cholesterol into the liposomes in serum was seen to have an 
augmenting effect on size (cholesterol is known to effect increases in size by interfacing between the lipid bilayers 
[24]). PDI values, ζ-potentials (typically 0.4 and -0.4 mV for DPPC and DSPC, respectively) did not appear to 
be influenced by liposome type or by the extent of o-carborane loading. 
To assess membrane integrity (stability), the retention of encapsulated calcein was evaluated for both 
types of DPPC and DSPC liposomes (with or without cholesterol). Measurements were made prior to and at 24 h 
following treatment with Triton X-100 (which disrupts the lipid bilayers) in PBS buffer (pH 7.4; Fig. 4). No 
statistical difference was found between the retention values of DPPC and DSPC liposomes in the absence or in 
the presence of cholesterol, irrespective of whether the experiment was conducted in PBS or in serum (ANOVA, 
p = 0.4929). Liposome stability appears to be little influenced by the type of liposomal constitutional unit (DPPC 
or DSPC). Also, it is strongly indicated that cholesterol does not bestow increased liposomal stability in PBS; and 
that the cholesterol-containing liposomes are similarly stable in serum and in PBS. Over the 24 hour timescale, 
there was no significant indication that liposomes in serum exhibit signs of degradation.  
 
3.6. Nile red experiments 
 
To assess if o-carborane had been incorporated into the liposomes in sufficient amounts for use in BNCT, Nile 
red, a fluorescent marker, was utilised as a displacement agent for o-carborane. DPPC and DSPC liposomes 
containing a fixed amount of Nile red (2.5 μM) and specified amounts of o-carborane were prepared and 
characterised in terms of particle size, PDI and ζ-potential (Table 4). The experiments demonstrate that liposomes 
were again prepared at the desired particle size (< 100 nm). DPPC particles were seen to be smaller than DSPC 
liposomes; PDI and ζ-potential values were consistent with those of other congener liposomes. Since the mean 
particle size increased with increasing o-carborane content, as observed previously, it would be reasonable to 
assume that the increasingly higher contents of o-carborane was successfully encapsulated in the liposomes. 
Fluorescence intensity measurements on liposome formulations, validated the technique: entrapped Nile red was 
indicated to occupy the available space of liposomes that had not been filled to saturation with o-carborane, as 
demonstrated by the inverse relationship between fluorescence intensity and o-carborane content (Fig. 5). 
Although the evidence is indirect and the data may only be regarded as semi-quantitative, there is strong evidence 
that the entire amount of o-carborane used in the preparation of the liposomes had been entrapped in all cases. To 
quantify o-carborane incorporation, the boron content was determined using ICP-MS 
 
3.7. ICP-MS measurements of o-carborane incorporation 
 
For both DPPC and DSPC liposomes (R2 = 0.987 and 0.992, respectively; Fig. 6) the data show a clear match 








Employment of the thin film method afforded o-carborane-containing DPPC or DSPC SUV liposomes with 
particle diameters of ca. 80 – 100 nm. Liposomes of DSPC had slightly larger average particle sizes than their 
DPPC congeners. For both DPPC and DSPC liposomes, average particle diameter increased with increasing 
amounts of entrapped o-carborane. All liposomes exhibited a monodispersed and homogeneous particle size 
distribution (PDI < 0.5). In PBS, both DPPC and DSPC probe-sonication-prepared liposomes exhibited ζ-
potentials that are in a range indicative of instability (between -30 and +30 mV) but the re-probing of samples has 
been shown to effect the formation of particles at the desirable size range (< 100 nm) that exhibit good stability 
on storage at 3 – 5 °C for at least one week. The effect of re-probing on stability was further demonstrated by 
AFM studies, which have shown that the loaded liposomes remain generally intact after 63 days of storage. 
Percentage retention experiments using a fluorescent marker (calcein) have shown that the integrity of the 
liposomal membrane in serum is high for both DPPC and DPPC liposomes that had been prepared using 
cholesterol as the stabilising agent. A combination of ICP-MS determinations and experiments involving the co-
entrapment into the liposomes of o-carborane and Nile Red have shown that in all cases boron content was 
quantitatively consistent with the amount that had been formulated into each liposomal sample. Future studies 
should be directed to the incorporation of cancer-targeted boron-compounds within the SUV liposomes and an 
investigation of their efficacy in vitro. 
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Figures and Tables 
 
Table 1. 
Lipid : o-carborane 1:40 1:20 1:10 1:1 1:0.5 1:0 
 
(a) DPPC 
        
n Probe        
1 Before d / nm 547.9 234.6 99.3 56.7 56.2 55.7 
PDI 1.000 0.608 0.318 0.204 0.352 0.242 
1 After d / nm 69.0 65.9 60.5 58.8 58.5 57.1 
PDI 0.105 0.116 0.48 0.155 0.266 0.273 
ζ / mV -0.365 -2.24 -1.04 -0.416 1.53 -1.39 
2 Before d / nm 114.5 106.9 88.74 85.04 65.35 61.75 
PDI 0.479 0.544 0.245 0.341 0.233 0.243 
2 After d / nm 81.5 80.6 70.1 64.8 63.0 60. 7 
PDI 0.357 0.413 0.168 0.199 0.115 0.259 
ζ / mV -4.31 -16.30 -16.50 -24.50 -35.20 -28.20 
3 Before d / nm 1046.0 136.4 99.9 89.2 78.6 74.3 
PDI 1.000 0.445 0.442 0.256 0.251 0.311 
3 After d / nm 75.5 50.2 44.1 43.5 42. 6 42.1 
PDI 0.171 0.243 0.3000 0.260 0.222 0.239 
ζ / mV -2.52 -13.50 -13.10 -22.90 -20.80 -20.40 
Mean 
± SD 
After d / nm 75.3±6.2 65.6±15.2 58.2±13.2 55.7±11.0 54.7±10.7 53.3±9.9 
PDI 0.21±0.13 0.26±0.15 0.32±0.16 0.210.26±0.05 0.20±0.08 0.26±0.02 
ζ / mV -2.40±1.98 -10.68±7.44 -10.21±8.12 -15.94±13.47 -18.16±18.51 -16.66±13.79 
(b) DSPC         
n Probe        
1 Before d / nm 150.5 146.9 145.1 94.7 93.2 82.8 
PDI 0.280 0.217 0.179 0.136 0.177 0.215 
1 After d / nm 111.0 105.8 96.51 93.5 82.7 59.5 
PDI 0.167 0.220 0.180 0.169 0.159 0.262 
ζ / mV -3.92 -5.46 -11.80 -23.7 -20.20 -7.88 
2 Before d / nm 150.8 136.9 132.9 91.0 81.7 79.0 
PDI 0.220 0.131 0.186 0.092 0.135 0.176 
2 After d / nm 98.3 97.3 96.3 90.1 76.7 71.3 
PDI 0.186 0.204 0.160 0.143 0.098 0.134 
ζ / mV -4.37 -12.40 -17.40 -3.21 -31.50 -22.30 
3 Before d / nm 588.4 130.3 79.7 73.0 86.9 80.5 
PDI 0.956 0.487 0.215 0.163 0.212 0.186 
3 After d / nm 85.8 81.4 64.3 39.3 39.0 38.8 
PDI 0.209 0.285 0.249 0.307 0.304 0.246 
ζ / mV -2.06 -16.00 -17.90 -2.99 -26.80 -21.00 
Mean 
± SD 
After d / nm 98.4±12.6 94.9±12.4 85.7±18.5 74.3±30.4 66.1±23.7 56.6±6.5 
PDI 0.19±0.02 0.24±0.04 0.20±0.05 0.21±0.01 0.19±0.11 0.21±0.07 







Lipid : o-carborane Before After 
 d / nm PDI d / nm PDI 
(a) DPPC     
1:40 262.0 ± 191.8 0.44 ± 0.33 394.9 ± 385.2 0.71 ± 0.30 
1:20 139.3 ± 37.6 0.41 ± 0.12 170.4 ± 62.5 0.31 ± 0.10 
1:10 100.7 ± 18.4 0.21 ± 0.06 120.2 ± 26.1 0.35 ± 0.20 
1:1 86.3 ± 4.6 0.26 ± 0.22 93.7 ± 4.8 0.19 ± 0.08 
1:0.5 83.4 ± 5.5 0.24 ± 0.02 106.1 ± 15.1 0.16 ± 0.01 
1:0 61.0 ± 19.5 0.30 ± 0.18 113.3 ± 28.8 0.43 ± 0.32 
(b) DSPC     
1:40 3917.2 ± 3614.7 0.46 ± 0.16 2225.4 ± 1839.2 0.51 ± 0.44 
1:20 2335.6 ± 2707.4 0.57 ± 0.44 3062.1 ± 3838.5 0.57 ± 0.43 
1:10 1802.1 ± 2347.4 0.61 ± 0.45 287.2 ± 187.7 0.42 ± 0.22 
1:1 245.0 ± 165.6 0.52 ± 0.35 95.7 ± 4.4 0.23 ± 0.13 
1:0.5 82.3 ± 5.5 0.09 ± 0.02 93.1 ± 4.8 0.27 ± 0.07 




 Mean d / nm 
Time / days DPPC unloaded DPPC loaded DSPC unloaded DSPC loaded 
1 86.4 ± 24.8 121.4 ± 26.7 83.3 ± 20.6 130.9 ± 26.2 
19 89.0 ± 37.2 103.2 ± 20.4 87.0 ± 24.0 108.3 ± 21.5 
35 83.6 ± 22.1 101.0 ± 28.0 66.5 ± 16.2 108.7 ± 22.6 
49 85.7 ± 21.4 62.0 ± 22.7 58.5 ± 15.4 89.4 ± 20.4 





 Mean ± SD 
Lipid : o-carborane d / nm PDI ζ / mV 
(a) DPPC    
0 63.3 ± 28.9    0.20 ± 0.02 0.02 ± 0.83 
1:0.5 65.8 ± 31.2    0.31 ± 0.09 -0.21 ± 0.91 
1:1 67.5 ± 29.4   0.21 ± 0.04 -1.71 ± 0.95 
1:10 73.8 ± 28.1 0.26 ± 0.09 -13.33 ± 10.14 
1:20 82.6 ± 24.5    0.16 ± 0.01 -14.78 ± 10.77 
1:40 87.6 ± 31.1 0.19 ± 0.01 -16.78 ± 9.65 
(b) DSPC    
0 71.9 ± 11.7 0.38 ± 0.00 -4.55 ± 4.55 
1:0.5 74.9 ± 15.3 0.29 ± 0.14 -3.81 ± 5.00 
1:1 77.2 ± 16.0 0.41 ± 0.04 0.38 ± 0.33 
1:10 88.9 ± 11.5 0.41± 0.08 -20.00 ± 4.53 
1:20 97.7 ± 19.0 0.29 ± 0.19 -12.70 ± 17.39 
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